Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ViiV/Janssen's Double-Edged SWORD: Four Drugs Good, Two Drugs Better?

Executive Summary

Data from ViiV Healthcare and Janssen's SWORD study point the way to a two-drug future in HIV for Tivicay/Edurant, but will doctors want to rock the boat, especially with Gilead's bictegravir impressing in Phase II?


Related Content

The Year's Clinical Trials In Review: Big Hits In 2017
GSK Spotlights Three Impending Drug Launches In 3Q Update
Keeping Track: HIV Filings Include Novel Agent From Gilead, Viiv's Two-Drug Maintenance Regimen


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts